~ Our portfolio

Our portfolio companies embody the Atlas culture of collaborative, science-first, patient-centric drug development

Seeded
Incubated
Co-founded
Next-generation gene therapies by enabling delivery of large genes
Visit Site
Targeting RNA-modifying proteins for novel precision cancer therapies
Visit Site Careers
Small molecule therapies for severe cardiovascular diseases

SWX: ATLN (2000)
Visit Site
Novel biologic drugs platform

Sold to BMS (2007)
Advancing novel therapies for people with rare cardiopulmonary disease

NASDAQ: AVTE (2021)
Visit Site Careers
Reimagining treatments for patients with respiratory illnesses and inflammatory conditions

Sold to GSK (2024)
Restoring metabolic balance to treat NASH and serious metabolic diseases

NASDAQ: AKRO (2019)
Visit Site Careers
RNAi-based drugs for severe diseases

NASDAQ: ALNY (2004)
Visit Site Careers
Novel anesthetics

Sold to The Medicines Company (2015)
Targeting progranulin and lysosomal biology to treat neurodegenerative diseases
Visit Site Careers
Novel cancer drugs using combinatorial chemistry

NASDAQ: ARQL (1996)
Visit Site
Migraine prevention therapy

Sold to Eli Lilly (2013)
Covalent irreversible inhibitors

Sold to Celgene (2012)
Cell and gene therapies for rare diseases

NASDAQ: AVRO (2018)
Visit Site Careers
Novel bicyclic peptides (bicycles) and bicycle drug conjugates for cancer

NASDAQ: BCYC (2019)
Visit Site Careers
Breakthrough therapies for neurological & psychiatric conditions

Sold to Novartis (2020)
Harnessing the power of the epigenome to develop precision genomic therapeutics
Visit Site Careers
Precision therapeutics for genetically defined diseases
Visit Site Careers
Our mission is to develop the first treatment targeting a root cause of preeclampsia
Visit Site
Novel antibodies for immuno-oncology

Sold to Novartis (2014)
Novel vaccine platform

Sold to Johnson & Johnson (2010)
Rapidly developing new cancer treatments for people of all ages

NASDAQ: DAWN (2021)
Visit Site Careers
Population genetics for the discovery of novel drug targets

Sold to Amgen (2012)
Visit Site Careers
Novel biologic therapeutics for autoimmune diseases

Sold to Celgene (2017)
Advancing a Ground-Breaking Approach to Agonist Antibody Therapeutics
Visit Site Careers
Preventing axonal degeneration in patients with neurological diseases

Sold to Lilly (2020)
Innovative treatments for hematologic diseases

NASDAQ: IRON (2022)
Visit Site Careers
Pioneering targeted therapies for serious muscle diseases

NASDAQ: DYN (2020)
Visit Site Careers
Functional genomics-based drug discovery

NASDAQ: EXEL (2000)
Visit Site Careers
Novel bispecific antibodies platform

Sold to invoX Pharma (2023)
Visit Site Careers
Scalable, re-dosable, non-viral gene therapy for genetic diseases

NASDAQ: GBIO (2020)
Visit Site Careers
Mouse platforms for the generation of fully human antibodies

Sold to Harbour BioMed (2016)
Therapies for rare and inflammatory diseases

NASDAQ: HZNP (2011)
Visit Site Careers
Unlocking nature's regulatory mechanisms to fuel the discovery of new medicines
Visit Site Careers
Targeting the innate immune system to treat cancer and inflammatory diseases

Sold to BMS (2017); Novartis (2019)
Visit Site Careers
Gene editing therapies

NASDAQ: NTLA (2016)
Visit Site Careers
Translating epigenetic modulation of oncogenic pathways into first-in-class small molecule therapeutics
Visit Site
Novel therapeutics for severe respiratory diseases
Visit Site
Delivering novel small molecule protein degrader medicines

Nasdaq: KYMR (2020)
Visit Site Careers
Among the first to leverage ADC success to develop treatments for autoimmune and inflammatory disorders
Visit Site
Novel therapies for severe neurodegenerative diseases

Sold to Bial in 2020
Treating cancer's toughest tumors through innovation in precision radiopharmaceuticals

Sold to Novartis (2024)
Visit Site Careers
Discovering precision covalent medicines for immune diseases
Visit Site Careers
Novel biologics for cancer treatment

Sold to Amgen (2012)
Development of complex biosimilar products

NASDAQ: MNTA (2004)
Novel antibody discovery platform

XETRA: MOR.DE (1999)
Visit Site Careers
Breakthrough computer-aided drug design for transformative medicines
Visit Site Careers
Novel antibiotics

Sold to AstraZeneca (2010)
Programmable, Non-Viral Platforms for In Vivo Delivery of Next Generation Genetic Medicines
Visit Site Careers
New class of regulated cell and gene therapies
Visit Site Careers
Novel medicines for auto-immune diseases

Sold to BMS (2016)
Targeting regulators of innate and adaptive immunity to restore immune homeostasis
Visit Site Careers
Restoring ABC transporter function for patients with serious genetic diseases
Visit Site Careers
Reprogramming RNA to address undruggable drivers of disease
Visit Site Careers
Next-generation oncolytic immuno-therapies for cancer treatment

NASDAQ: REPL (2018)
Visit Site Careers
Enhancing synaptic integrity for treatment of neurological disorders

Sold to Alkermes (2019)
Developing highly effective and differentiated treatments for cystic fibrosis
Visit Site Careers
Novel antibiotics for drug-resistant bacterial infections

NASDAQ: SPRO (2017)
Visit Site Careers
Novel fibrosis therapeutic

Sold to Biogen Idec (2012)
Novel antibodies built to break through the tumor microenvironment

Sold to Coherus (2023)
Visit Site
Pioneering transformative new biotherapeutics for patients

NASDAQ: SYBX (2017)
Visit Site Careers
Advancing medicines for allergy and inflammation

NASDAQ: THRD (2022)
Visit Site Careers
mRNA vaccines and therapies

Sold to Sanofi (2021)
Target-first, rational molecular glue drug discovery platform
Visit Site Careers
Novel antibodies for the treatment of I&I disorders
Visit Site
Next-generation ocular gene therapies for vision restoration and preservation

Sold to Novartis (2020)
Transformative treatments for people with obesity and other cardiometabolic diseases

Sold to Lilly (2023)
Harnessing the power of microglia to transform treatments for neuro-degenerative diseases

NASDAQ: VIGL (2022)
Visit Site Careers
Novel therapeutics using proprietary computational chemistry

Sold to Allergan (2016)
Harnessing the immune system to defeat cancer with tumor-selective immunotherapies

NASDAQ: XLO (2021)
Visit Site Careers